anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Coronary heart disease (CHD) is the leading cause of mortality worldwide. Every year, millions of people suffer its most adverse manifestation, an acute myocardial infraction (AMI). The majority of these patients present at least one of the standard modifiable risk factors (SMuRFs). These include smoking, hypertension, dyslipidemia, and diabetes mellitus (DM). However, emerging scientific evidence recognizes a clinically significant proportion of patients presenting with life-threatening AMI without any SMuRF (SMuRF-less patients). This proportion of patients with ACS without SMuRF appears to be increasing during the last two decades and has recently been reported as high as 20% (of total AMIs). To date, there are no scientific data capable of highlighting specific risk factors-biomarkers responsible for the development of AMIs SMuRF-less patients.

Concurrently, metabolomics is rapidly evolving as a novel technique of studying small molecule substrates, intermediates and products of cell metabolism. This technique could be utilized to flag patients with higher risk for increased atherosclerotic burden, and subsequent future adverse clinical events. Besides the already established biomarkers, several metabolomic indicators, such as ceramides (C16, C18 και C24), acylcarnitines, apolipoproteins (ApoΒ and ApoA1) and adiponectin, have been separately shown to increase the risk for coronary artery disease development and progression. Therefore, the two groups of patients (with SMuRFs vs SMuRF-less) will be compared regarding their metabolic fingerprints -specifically the aforementioned novel metabolomic biomarkers- and possible predictive factors leading to SMuRF-less AMI will be evaluated. On the basis of the above, the aim is to prospectively analyze a cohort of well-characterized patients with AMI. The rationale of the study is to investigate potential correlations between metabolic profile of patients and SMuRF-less AMI. This could lead to the development of predictive risk stratification algorithms for patients without SMuRFs and coronary artery disease.

Blood tests (blood chemistry) will be received from each patient on admission and will be analyzed to assess patients' metabolic profile. In order to achieve full coverage of all compounds, different analytical platforms and methods, such as Enzyme-LInked Immunosorbent Assay (ELISA), Reversed Phase Liquid Chromatography tandem Mass Spectrometry (RPLC-MS/MS) and Hydrophilic Interaction Liquid Chromatography tandem Mass Spectrometry (HILIC-MS/MS) will be applied. Univariate and multivariate analysis with linear and logistic regression models will be used to investigate independent prognostic factors contributing to the occurrence of SMuRF-less AMIs. The potential application in daily clinical practice of a derived clinical predictive model-algorithm, possibly including a new panel of metabolomic biomarkers, will contribute to the early prognosis and personalized prevention of such a particular category of AMIs.
FIELD: medicine. SUBSTANCE: method includes removal of nail plate, antibacterial treatment of nailbed and its therapy. Nailbed is coated with dilixide-containing compound with alternation of its composition. Area of growing nail rear wall and root is exposed to supersonic- frequency currents. Generally-strengthening and antimycotic therapy is selected by means of electric puncturing diagnostics by method of R.Foll. Type of fungous infection is determined by nosodes. Then bioresonance therapy is carried out with aid of homeopathic and organic preparations. EFFECT: reduced terms of treatment. 3 cl, 1 ex
Only intramuscular injection was applied to this patients. Intramuscular injectable form of Lidocaine Hydrochloride (20mg/ml, Jetokain Simplex, ADEKA, Samsun, Turkey) was injected. 0,3 ml was injected to all trigger points.
Medications and genetics have been identified as research priorities by NIAAA. The present application proposes to test two genetic-drug matching hypotheses to better understand heterogeneity among alcoholics. Previous basic science, treatment and genetic research suggests that active drinkers with the LL genetic variant of the serotonin transporter 5'-HTTLPR (a hypothesized genetic risk factor for early onset alcoholism) will respond better to ondansetron than sertraline or placebo. Conversely, active drinkers with the SS or SL genetic variant of the serotonin transporter 5'-HTTLPR (a hypothesized genetic risk factor for late onset alcoholism) will respond better to sertraline than ondansetron or placebo. The objective of this research is to match and mismatch serotonergic treatments to genetic polymorphic variants in a double-blind placebo controlled 2 x 2 design laboratory study where the 2 arms will be counterbalanced. The specific aims are to investigate: (1) whether LL-carriers receiving ondansetron results in a significant reduction in alcohol consumption during an alcohol self-administration experiment (ASAE) and during the period of treatment; (2) whether SL and SS-carriers receiving sertraline will result in a significant reduction in alcohol consumption during an ASAE and during the period of treatment; (3) examine mechanism of action for craving and subjective effects during the ASAE sessions: (4) whether there is a reduction in alcohol consumption during the ASAEs in the presence of the LG, and LA 5-HTTLPR variants and when LL participants receive ondansetron or when LL participants receive sertraline; (5) if the primary aims are moderated by the presence of the C (-1019) G polymorphism of the 5-HT1A gene promoter. We propose to randomize 132 non-treatment-seeking alcohol dependent participants based on their 5'-HTTLPR variant genotype (LL or SS/SL) into one of two counterbalanced arms: e.g. subjects in the first arm will first receive one drug (either 200mg/day of sertraline or ondansetron 0.5mg/day) for three weeks followed by an ASAE, then receive placebo for three weeks (this will be a single-blind portion to use as a comparison group and to wash out the pharmacodynamic effects of the first drug) followed by a second ASAE. Finally, participants will receive the second drug for three weeks followed by a third ASAE. Volunteers in the second arm will receive the same medications in a counter-balanced fashion. There will be a 1-week down titration after the first and third segments for all subjects. The long-term objective of this proposed research is to examine serotonergic treatment matching for alcohol dependence based on genotyping, and begin to investigate patient variation when matched prospectively with one serotonergic treatment or the other.
The exact incidence of cervicobrachial pain syndrome is not known due to the paucity of population-based studies, patients suffering the symptoms of this condition frequently attend for physiotherapy.

In the scientific literature, cervicobrachial pain is the presence of pain in the neck that radiates or refers to the arm. It is considered as common spine disorder with upper quadrant pain due to muscles, joints or intervertebral discs. Upper quadrant discomfort involves neck, shoulder, arm, upper back but neural tissue sensitivity to mechanical stimuli portrays to be the essential element of cervicobrachial pain. It generally refers to neck pain that along with paresthesia is radiating to one upper extremity and leading to muscle imbalances. Elvey planned some clinical tests to recognize the problems of neurogenic disorders that are responsive to non-intrusive physical therapy treatment. The acceptability of these tests from effective treatments has not been adequately proven yet.

According to the literature cervical lateral glide is considered as first line treatment in reducing pain and improving upper limb function and is specifically very effective in patients of cervicobrachial pain syndrome. Cervical lateral glide has hypoalgesic effect on neck and arm pain. It is thought that this technique stimulates cervical afferents which can affect pain processes at spinal cord and cortical levels. A study was conducted in which passive techniques for mobilizing neural tissue and cervical spine were given as direct manual therapy treatment. Thoracic mobilization corresponds to indirect neural mobilization that is effective in reducing pain and functional limitations when incorporated with cervical spine mobilization that is referred as direct neural mobilization in patients of cervicobrachial pain. Evidence suggests that improvement in cervical stability and thoracic mobility achieved through manual therapy is significant in reducing neck pain and improving functional motion This study would help to investigate the delineation between specific and non-specific components of manual therapy. This study aims to compare the effects of direct neural tissue technique that is cervical lateral glide mobilization along with indirect neural tissue mobilization technique that is thoracic mobilization on pain, range of motion, endurance of neck flexors and functional ability in patients with cervicobrachial pain.
Neurocognitive difficulties are a common problem in the older adult population. Previous research has shown memory complaints are higher in older adults with depression or anxiety versus those without these diagnoses. This suggests that mood symptoms, or a diagnosis of a mood disorder, may represent significant predictors of cognitive impairment. If left untreated, symptoms of depression and memory complaints may lead to greater cognitive impairment, i.e. Mild Cognitive Impairment (MCI) and diagnosis of dementia. Therefore, early interventions are urgently needed to prevent decline in memory and cognitive function in individuals with MCI, depression and/or anxiety.

Ideal interventions for the older aged population would be those that are easily accessible and associated with minimal burden on family members, the healthcare system and the individuals themselves. Mindfulness- Based Stress Reduction (MBSR) therapy and Transcranial Direct Current Stimulation (tDCS) are two interventions that may be effective in targeting cognitive deficits in individuals with anxiety, depression and/ or cognitive complaints. MBSR has been shown to decrease symptoms of depression and improve cognition and tDCS has been shown to improve cognition in the older aged population. The effectiveness of these two interventions combined to elicit changes in cognition has yet to be demonstrated. Therefore, the overall aim of the current research is to evaluate the efficacy of a combination of MBSR and tDCS to improve cognitive function in individuals with anxiety, depression and/or cognitive complaints.

This will be a randomized pilot study. Sixteen individuals (separated into 2 groups of 8) will be randomized to receive a combination of MBSR + active tDCS or MBSR + sham tDCS over 8 weeks. Participants will visit the Healthy Mind Lab once per week for in-class group sessions and will complete the intervention daily at home for the duration of the study. Participants will be aged 60 and older with cognitive complaints, with or without symptoms of anxiety and/or depression. Participants will be trained to self-administer tDCS and given guidelines for the completion of daily MBSR activities at home. It is hypothesized that the combination of active tDCS+MBSR will enhance cognition compared to the combination of sham tDCS + MBSR.
The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option.
Patients in treatment arm A will receive a dose of 300 mg secukinumab administered as 2 subcutaneous injections of 150 mg in a SensoReady pen (i.e. 2 x 150 mg) at weeks 0, 1, 2, 3, 4, 8, 12, 16 and 20.
An equine gastric health formulation that is operable to heal gastrointestinal disorders such as but not limited to ulcers, wherein the present invention further improves liver function and detoxification of the horse. The formulation of the present invention in a preferred embodiment is water based wherein fifty percent of the formulation is distilled water which is approximately five hundred milliliters. A concentration of one percent of the total solution is formed by origanum vulgare. Another two percent of the formula being represented equally is silybum marianum and taraxacum. Three drops of mentha piperita are also dispensed into the formulation of the present invention. Wherein the formulation includes ten percent of chlorophyllin and thirty seven percent is camelina oil. Additionally, four tablespoons of acacia gum powder are mixed into the formulation.
PURPOSE:To obtain a detergent composition, comprising a specific spherical fine granular inorganic pigment and ethylene glycol ester of a fatty acid and excellent in stability, detergency and usability. CONSTITUTION:This detergent composition comprises 0.01-10wt.% spherical fine granular inorganic pigment having 0.1-100mum average grain diameter and >=0.5ml/g oil absorption (e.g. silicic acid anhydride) and 0.1-10wt.% ethylene glycol ester of a fatty acid (e.g. ethylene glycol distearate) as active ingredients. The spherical fine granular inorganic pigment is prevented from separating and flocculating by using the ethylene glycol ester of the fatty acid and pearly luster can be imparted to a product. The detergent composition is capable of manifesting clean washing finish with hardly any sliminess after use without any irritation and damage to the skin and widely usable as a skin detergent such as a detergent for the whole body, a bar soap or a face washing preparation, a detergent, etc., for tableware or contact lenses.
Placebo oral capsules. Five capsules the first day and thereafter one capsule every week for 4 months.
Malnutrition is linked to adverse outcomes in post-cardiac surgery patients. This study investigates the correlation between the Geriatric Nutritional Risk Index (GNRI) and adverse hospital outcomes in patients following cardiac surgery. This retrospective study included elderly patients with heart disease who were admitted to the Department of Cardiology, Fujian Medical University Union Hospital from January 2020 to December 2022. Patients were divided into two groups based on the cut-off value (98 g/dL). Data from 407 patients were assessed, with 278 (68.3%) classified as having nutritional risk and 129 (31.7%) as having no nutritional risk. Notable distinctions were observed in body weight, BMI, and left ventricular ejection fraction (P < 0.05). Laboratory indicators indicated lower levels of serum albumin, lymphocytes, red blood cells, hemoglobin, admission blood glucose, and admission triglyceride in the nutritional risk group (P < 0.05). Neutrophils and serum creatinine were higher in the nutritional risk group (P < 0.05). Poor prognosis was prevalent in the nutrition risk group (64.7%), with higher incidences of adverse outcomes (P < 0.05). Univariate and multivariate studies showed that GNRI < 98 g/dL was an independent predictor of postoperative cardiac surgery. Nutritional risk was an important predictor of adverse hospital outcomes after the surgery.
The invention belongs to the technical field of biomedicine. So far, no report on bioactive peptides of Hydrophis cyanocinctus exists. The invention provides an anti-inflammatory active peptide Hydrostatin-SN1 derived from Hydrophis cyanocinctus. The anti-inflammatory active peptide Hydrostatin-SN1 derived from Hydrophis cyanocinctus contains a protein having an amino acid sequence shown as SEQ ID NO.1. The invention further provides a coding gene of Hydrostatin-SN1 and the application of anti-inflammatory active peptide Hydrostatin-SN1 derived from Hydrophis cyanocinctus and coding gene thereof for preparing medicaments for treatment of TNF-alpha-related diseases. The TNF-alpha-related diseases may include rheumatoid arthritis, diabetes, coronary heart disease, sepsis, colonitis and other complicated inflammation or immunological diseases. The anti-inflammatory active peptide Hydrostatin-SN1 derived from Hydrophis cyanocinctus and coding gene thereof are significant in clinical applications.
Double dummy technique was employed requiring a large number of tablets and water to be consumed. Participants were instructed to take 2 matching Mucinex placebo tablets combined with 1 matching IR guaifenesin placebo tablet by mouth, every 6 hours for 7 days.
Participants received placebo gel (0.2gm) applied following a single surgilance to the 5th digit. The placebo gel was applied 10 minutes following the first lance, rubbed in for one minute within an 8 mm mold surrounding the lance site. The mold was removed and the gel was covered with a transparent occlusive dressing and left in place for 30 minutes. The forearm was also swabbed with the placebo gel which was left in place for 30 minutes. .The placebo gel contained the same ingredients without the loperamide. The placebo gel formulation includes: Propylene Glycol; Ethanol (190 proof USP); Ethyl acetate; and Klucel HF 1%.
Novel cationic amphiphiles are provided that facilitate transport of biologically active (therapeutic) molecules into cells. The amphiphiles contain lipophilic groups derived from steroids, from mono or dialkylamines, or from alkyl or acyl groups; and cationic groups, protonatable at physiological pH, derived from amines, alkylamines or polyalkylamines. There are provided also therapeutic compositions prepared typically by contacting a dispersion of one or more cationic amphiphiles with the therapeutic molecules. Therapeutic molecules that can be delivered into cells according to the practice of the invention include DNA, RNA, and polypeptides. Representative uses of the therapeutic compositions of the invention include providing gene therapy, and delivery of antisense polynucleotides or biologically active polypeptides to cells. With respect to therapeutic compositions for gene therapy, the DNA is provided typically in the form of a plasmid for complexing with the cationic amphiphile.Novel and highly effective plasmid constructs are also disclosed, including those that are particularly effective at providing gene therapy for clinical conditions complicated by inflammation. Additionally, targeting of organs for gene therapy by intravenous administration of therapeutic compositions is described.
Background Gastroesophageal reflux disease (GERD) is among the most common complications of bariatric surgery. This study aimed to analyse the risk factors affecting the worsening of GERD symptoms after laparoscopic sleeve gastrectomy (LSG), and to establish and validate a related nomogram model. Methods The study recruited 236 participants and randomly divided them into training and validation sets in a ratio of 7:3. LASSO regression technique was used to select the optimal predictive features, and multivariate logistic regression was used to construct the column line graphs. The performance of the nomogram was evaluated and validated by analyzing the area under the receiver operating characteristic (ROC) curve, calibration curve, and decision curve. Results In this study, Lasso-logistic regression was applied to select 5 predictors from the relevant variables, which were body mass index (BMI), diabetes, hiatal hernia, GERD, and triglyceride levels. These 5 predictor variables constructed a model with moderate predictive power, with an area under the ROC curve of 0.779 for the training set and 0.796 for the validation set. Decision curve analysis showed that in external validation, if the risk thresholds were between 4 and 98% and 14-95%, then the nomogram can be applied to the clinic. Conclusions We have developed and validated a nomogram that effectively predicts the risk of worsening gastroesophageal reflux symptoms following LSG.
This study proposes to describe the practices, attitudes, and beliefs of genetic counselors in relation to suicide risk assessment (SRA) of their adolescent clients. Suicide is a major public health issue and one of the leading causes of death for adolescents in the U.S. Analysis of suicide prevention campaigns has shown that the most effective way to decrease suicide is by training physicians to recognize suicide risk factors in their patients . However, pediatricians do not consistently screen youth for suicide risk during routine check-ups. As chronic illness is an additional risk factor for suicide, pediatric genetic counselors encounter particularly high-risk clients and are well-positioned to assess for suicide risk due to the psychosocial nature of their work. However, the SRA practices of genetic counselors are largely unknown. In this study, the Transtheoretical Model of Behavior Change is used as a framework to describe how genetic counselors SRA self-efficacy and perceptions of the pros and cons of SRA relate to stages of readiness and practices of assessing clients for suicide risk. Specifically, we will be surveying genetic counselors about their practices, attitudes and beliefs concerning SRA of adolescent clients. First, we will determine genetic counselors frequency of SRA and their stage of readiness for routine screening. Second, we will measure genetic counselors SRA self-efficacy and their perceptions of the pros and cons of screening their clients. We will examine whether self-efficacy and perceptions of pros and cons are predictors of genetic counselors stage of readiness for routine suicide screening. Finally, we will qualitatively assess genetic counselors perceptions of the usability of a validated suicide screening tool (the ASQ) in genetic counseling sessions and their interest in receiving suicide screening training. We will use a cross-sectional, mixed-methods design in which counselors will complete an online questionnaire with quantitative components and open-ended responses. Participants will be recruited through the National Society of Genetic Counselors Student Research Survey listserv.
Pembrolizumab will be administered intravenously at a dose of 200 mg every 3 weeks starting week 4. Sylatron will be administered at a dose of 200mcg subcutaneously weekly starting at week 1.
Group 1 will receive treatment in a physiotherapy unit which has following characteristics ; enlightened with sunlight, has a view of green trees and includes other participants exercising. Patients will receive a treatment consisting of patient education, exercise therapy and cold application for a total of 15 sessions, 3 times a week. Each session will last approximately 60 minutes. After the patient education and exercise therapy is completed, the participants will listen to classical music pieces selected by us during 15 minutes of cold application.
Perform conventional continuous curvilinear capsulorhexis. After phacoemulsification and I/A, inject viscoelastic agent and implant IOL without polish. Use I/A instrument to remove viscoelastic agent. A 27G irrigating syringe was used, and the RLFs on the posterior capsule were gently aligned to make a fluid-jet basically parallel to the iris. The liquid pressure of 50-120 mmHg is produced. The standard for stopping in this mode is that the RLFs can no longer be washed down from the capsule, or there are no discernible RLFs on the posterior capsule. All operations are videotaped during the whole operation. The total time of all jet procedures recorded in the videotape is the total time of jet.